Evidence map›Paper›PMID 34836952›Full record

Observational studyNature communications2021

Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes.

Naser Ansari-Pour, Yonglan Zheng, Toshio F Yoshimatsu, Ayodele Sanni, Mustapha Ajani, Jean-Baptiste Reynier, Avraam Tapinos, Jason J Pitt, Stefan Dentro, Anna Woodard and 18 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 13 institutions in 5 countries.

Naser Ansari-Pour *Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7LF, UK.ORCID 0000-0003-0908-0484
Yonglan Zheng *Center for Clinical Cancer Genetics and Global Health, Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA.ORCID 0000-0001-6597-7072
Toshio F YoshimatsuCenter for Clinical Cancer Genetics and Global Health, Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA.ORCID 0000-0003-2674-8159
Ayodele SanniDepartment of Pathology and Forensic Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.
Mustapha AjaniDepartment of Pathology, University of Ibadan, Ibadan, Oyo, Nigeria.ORCID 0000-0001-5758-5773
Jean-Baptiste ReynierCenter for Clinical Cancer Genetics and Global Health, Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA.
Avraam TapinosManchester Cancer Research Centre, University of Manchester, Manchester, M20 4GJ, UK.
Jason J PittCancer Science Institute of Singapore, National University of Singapore, Singapore, 117599, Singapore.
Stefan DentroEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Cambridge, CB10 1SD, UK.
Anna WoodardCenter for Clinical Cancer Genetics and Global Health, Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA.
Padma Sheila RajagopalCenter for Clinical Cancer Genetics and Global Health, Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA.
Dominic FitzgeraldInstitute for Genomics and Systems Biology, University of Chicago, Chicago, IL, 60637, USA.
Andreas J GruberBig Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7LF, UK.
Abayomi OdetundeInstitute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria.
Abiodun PopoolaOncology Unit, Department of Radiology, Lagos State University, Ikeja, Lagos, Nigeria.
Adeyinka G FalusiInstitute for Advanced Medical Research and Training, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria.
Chinedum Peace BabalolaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Ibadan, Ibadan, Oyo, Nigeria.ORCID 0000-0001-9173-8032
Temidayo OgundiranDepartment of Surgery, University College Hospital, Ibadan, Oyo, Nigeria.
Nasiru IbrahimDepartment of Surgery, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.
Jordi BarretinaGirona Biomedical Research Institute (IDIBGI), Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain.ORCID 0000-0002-3478-4080
Peter Van LooThe Francis Crick Institute, London, NW1 1AT, UK.ORCID 0000-0003-0292-1949
Mengjie ChenDepartment of Human Genetics, The University of Chicago, Chicago, IL, 60637, USA.ORCID 0000-0003-1579-087X
Kevin P WhiteTempus Labs Inc., Chicago, IL, 60654, USA.
Oladosu OjengbedeCentre for Population and Reproductive Health, College of Medicine, University of Ibadan, Ibadan, Oyo, Nigeria.
John ObafunwaDepartment of Pathology and Forensic Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, Nigeria.
Dezheng HuoDepartment of Public Health Sciences, The University of Chicago, Chicago, IL, 60637, USA.ORCID 0000-0002-4041-1678
David C WedgeBig Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, OX3 7LF, UK. david.wedge@manchester.ac.uk.ORCID 0000-0002-7572-3196
Olufunmilayo I OlopadeCenter for Clinical Cancer Genetics and Global Health, Department of Medicine, The University of Chicago, Chicago, IL, 60637, USA. folopade@medicine.bsd.uchicago.edu.ORCID 0000-0002-9936-1599
University of Chicago · USUniversity of Ibadan · NGLagos State University Teaching Hospital · NGUniversity of Manchester · GBChicago Department of Public Health · USEuropean Bioinformatics Institute · GBInstitut d'Investigació Biomèdica de Girona · ESLagos State University · NGNational University of Singapore · SGTempus Labs (United States) · USThe Francis Crick Institute · GBUniversity College Hospital, Ibadan · NGUniversity of Oxford · GB

Funding

Polygenic Risk Prediction of Breast Cancer for Women of African DescentR01CA228198 · NCI · UNIVERSITY OF CHICAGO · PI Dezheng Huo · 2018 to 2026
$3.9M
Using Genomics to Reduce Breast Cancer Disparities in the African DiasporaU01CA161032 · NCI · UNIVERSITY OF CHICAGO · PI HUO, DEZHENG, OLOPADE, OLUFUNMILAYO F. · 2012 to 2015
$3.6M
UChicago Interdisciplinary Cancer Health Disparities SPOREP20CA233307 · NCI · UNIVERSITY OF CHICAGO · PI HUO, DEZHENG · 2018 to 2020
$3.4M
Etiology and Genomics of Breast Cancer Progression in Women of African AncestryR01MD013452 · NIMHD · UNIVERSITY OF CHICAGO · PI HUO, DEZHENG, OLOPADE, OLUFUNMILAYO F. · 2019 to 2023
$2.8M
Cancer Research UKMedical Research CouncilNCI NIH HHS P20 CA233307NCI NIH HHS R01 CA228198NCI NIH HHS U01 CA161032NIMHD NIH HHS R01 MD013452Wellcome Trust 203141/Z/16/ZWellcome Trust FC001202
6 · The paper itself

Abstract

Black women across the African diaspora experience more aggressive breast cancer with higher mortality rates than white women of European ancestry. Although inter-ethnic germline variation is known, differential somatic evolution has not been investigated in detail. Analysis of deep whole genomes of 97 breast cancers, with RNA-seq in a subset, from women in Nigeria in comparison with The Cancer Genome Atlas (n = 76) reveal a higher rate of genomic instability and increased intra-tumoral heterogeneity as well as a unique genomic subtype defined by early clonal GATA3 mutations with a 10.5-year younger age at diagnosis. We also find non-coding mutations in bona fide drivers (ZNF217 and SYPL1) and a previously unreported INDEL signature strongly associated with African ancestry proportion, underscoring the need to expand inclusion of diverse populations in biomedical research. Finally, we demonstrate that characterizing tumors for homologous recombination deficiency has significant clinical relevance in stratifying patients for potentially life-saving therapies.

Indexed as

Clonal EvolutionHealth Status DisparitiesAdultAgedBiomarkers, TumorBiopsyBlack PeopleBreastBreast NeoplasmsDNA Mutational AnalysisFemaleGATA3 Transcription FactorGenetic HeterogeneityGenomic InstabilityGerm-Line MutationHumansBiomarkers, TumorGATA3 protein, humanGATA3 Transcription FactorSynaptophysinSYPL1 protein, humanTrans-ActivatorsZNF217 protein, human

Identifiers

PMID34836952
PMCPMC8626467
OpenAlexW3215318424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.